Geriatric Medicine Development Market - Global Industry Analysis and Strategy

1
Geriatric Medicine Development - Carving out New
Opportunities to Treat Age-related Diseases
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• The biosimilars market is undergoing rapid change
  with developments such as the recent approvals of
  infliximab and trastuzumab heralding a new era.
• More than 50 of prescriptions is written for
  people aged 65 years and older. Many older people
  suffer from comorbid conditions and one in three
  takes at least five drugs or more on a daily
  basis. This significantly increases the risk of
  Adverse Drug Events (ADEs) and hospitalization.
  Up to one third of emergency admissions in
  elderly people is drug-related.
• There remains a lack of clinical data to support
  prescription decisions as relatively few
  medicines have been clinically evaluated in
  age-appropriate patients. In addition, many drugs
  are not available in formulations that are
  suitable for the elderly, leading to
  non-compliance and lack of therapeutic efficacy.
  In 2011, the EMA introduced its Geriatric
  Medicines Strategy to ensure that the medical
  requirements of older people are identified
  earlier in the drug development process. In 2012,
  the ICH E7 guidelines were revised to include a
  greater focus on involving more geriatric
  patients in drug trials.
• Read More At http//www.researchbeam.com/geriatr
  ic-medicine-development-carving-out-new-opportunit
  ies-to-treat-age-related-diseases-market

3


Report Overview

• Scope
• Reviews the current regulatory landscape and
  helps sponsors to understand the potential impact
  of recent guidelines.
• Assesses the barriers to entry in geriatric
  medicines and identifies potential ways to
  overcome them and improve clinical decision
  making.
• Evaluates the importance of establishing Target
  Quality Product Profiles (TQPP) to help sponsors
  determine the target patient population earlier
  on in drug development.
• Identifies treatment gaps and commercial
  opportunities based on primary care real-time
  data and KOL insights.
• - Analyses different strategies to develop
  age-appropriate medicines in niche therapeutic
  fields and discusses methods to encourage the
  smarter prescription of medicines.

4


Table of Content
Executive SummaryMethodologyGeriatric
medicines an overviewEmerging issuesUnmet
clinical needsCurrent landscapeRegulatory
environmentPolitical will for changeStrategic
considerations for developing geriatric
medicinesBarriers to developing geriatric
drugs Clinical trial considerationsâœBig
dataâsâ